PRRUF
IMMUTEP LTD ORD by Immutep Ltd. (PRRUF)
$20
About IMMUTEP LTD ORD by Immutep Ltd. (PRRUF)
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$0.28
52 Week Low
$0.17
Market cap
292.1M
Dividend yield
0.00%
Volume
--
Avg. volume
0
P/E ratio
-9.17
IMMUTEP LTD ORD by Immutep Ltd. News
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$0.28
52 Week Low
$0.17
Market cap
292.1M
Dividend yield
0.00%
Volume
--
Avg. volume
0
P/E ratio
-9.17